Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Assets (2016 - 2025)

Abeona Therapeutics (ABEO) has 15 years of Current Assets data on record, last reported at $216.1 million in Q3 2025.

  • For Q3 2025, Current Assets rose 91.85% year-over-year to $216.1 million; the TTM value through Sep 2025 reached $216.1 million, up 91.85%, while the annual FY2024 figure was $100.9 million, 80.94% up from the prior year.
  • Current Assets reached $216.1 million in Q3 2025 per ABEO's latest filing, down from $232.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $232.3 million in Q2 2025 and bottomed at $25.5 million in Q3 2022.
  • Average Current Assets over 5 years is $83.3 million, with a median of $66.7 million recorded in 2024.
  • Peak YoY movement for Current Assets: plummeted 62.45% in 2022, then skyrocketed 185.9% in 2024.
  • A 5-year view of Current Assets shows it stood at $56.3 million in 2021, then dropped by 5.67% to $53.1 million in 2022, then grew by 4.97% to $55.7 million in 2023, then skyrocketed by 80.94% to $100.9 million in 2024, then skyrocketed by 114.3% to $216.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $216.1 million in Q3 2025, $232.3 million in Q2 2025, and $88.1 million in Q1 2025.